Sign in or Join FriendFeed
FriendFeed is the easiest way to share online. Learn more »
Libby's H*O*P*E*

Libby's H*O*P*E*

Libby's H*O*P*E* (*Helping *Ovarian Cancer Survivors *Persevere Through *Education). To learn more go to
AstraZeneca ovarian cancer drug olaparib (Lynparza) wins European green light. .... | Reuters -
Nanoconstructs Aid Ovarian Cancer Targeting. ....... | Research & Technology | Oct 2014 | -
Hospice increase doesn't offset end-of-life care for ovarian cancer. ...... - ONA -
UConn Researchers Develop Personalized Ovarian Cancer Vaccines. ...... | UConn Today -
New test can help doctors choose best treatment for ovarian cancer. .... -
Comparison of Pure and Mixed-Type Clear Cell Carcinoma of the Ovary: A Clinicopathological Analysis of 341 Chinese Patients. ....... [Int J Gynecol Cancer. 2014] - PubMed - NCBI -
Carcinosarcomas in female genital tracts: general review... [Bull Cancer. 2014 Jul-Aug] - PubMed - NCBI -
Malignant transformations in ovarian teratomas: a report of four cases.... [J Pak Med Assoc. 2014] - PubMed - NCBI -
Vitamin D Suppresses Leptin Stimulation of Cancer Growth through MicroRNA. ...... [Cancer Res. 2014] - PubMed - NCBI -
SGN-LIV1A: A Novel Antibody-Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer. ... [Mol Cancer Ther. 2014] - PubMed - NCBI -
These results support the clinical evaluation of SGN-LIV1A as a novel therapeutic agent for patients with LIV-1 expressing cancer, including breast, prostate, ovarian and uterine cancers, as well as melanoma). - Libby's H*O*P*E*
Survival Advantage Associated with Decrease in Stage at Detection from Stage IIIC to Stage IIIA Epithelial Ovarian Cancer.... [J Oncol. 2014] - PubMed - NCBI -
Single institution study found that decreasing stage at detection from Stage IIIC to stage IIIA epithelial ovarian cancer is associated with a 5-year survival advantage of nearly 20% in patients treated by surgical tumor cytoreduction and platinum-based chemotherapy. - Libby's H*O*P*E*
Catumaxomab for the Treatment of Malignant Ascites in Patients With Chemotherapy-Refractory Ovarian Cancer: A Phase II Study.... [Int J Gynecol Cancer. 2014] - PubMed - NCBI -
Mechanisms by Which Low Glucose Enhances the Cytotoxicity of Metformin to Cancer Cells Both In Vitro and In Vivo.... [PLoS One. 2014] - PubMed - NCBI -
Ovarian cancer oncogene FAL1 found in 'junk DNA'. ...... - ONA -
A Functional Genomic Approach Identifies FAL1 as an Oncogenic Long Noncoding RNA that Associates with BMI1 and Represses p21 Expression in Cancer. ......: Cancer Cell -
Maintenance Pazopanib in Ovarian Cancer: No Survival Benefit, High Rate of Complications. .... | Ovarian Cancer Research Fund -
Stanford licenses promising cancer drug to local biotech startup. .... - SFGate -
Mercy Medical Center Announces Opening of New Lya Segall Ovarian Cancer Institute. ... -
Mercy To Open New Ovarian Cancer Institute. .... - Dr. Rosenshein - Baltimore, Maryland -
Keck Medicine of USC researchers discover dual purpose of cancer drug in regulating expression of genes. .....Detail -
Penn Researchers Explain How Ends of Chromosomes are Maintained for Cancer Cell Immortality. ..... -
Effect of Ultrasound Sonication on Clonogenic Survival and Mitochondria of Ovarian Cancer Cells in the Presence of Methylene Blue. ...... -
Simple blood test could be used as tool for early cancer diagnosis. ...... Bristol University | News | September: -
Chemists recruit anthrax to deliver cancer drugs -- With some tinkering, a deadly protein becomes an efficient carrier for antibody drugs. ...... | MIT News Office -
A Way to Kill Chemo-Resistant Ovarian Cancer Cells: Cut Down Their Protector -
How Can Women Reduce Their Risk of Ovarian Cancer? .....- YouTube -
Epigenetic silencing of ARNTL, a circadian gene and potential tumor suppressor in ovarian cancer. ..... [Int J Oncol. 2014] - PubMed - NCBI -
The pathogenesis of atypical proliferative Brenner tumor: an immunohistochemical and molecular genetic analysis. ...... [Mod Pathol. 2014] - PubMed - NCBI -
Pressurized intraperitoneal chemotherapy (PIPAC) in women with gynecologic malignancies: a review. ..... [Wien Med Wochenschr. 2014] - PubMed - NCBI -
An anti-mesothelin-monomethyl auristatin E conjugate with potent anti-tumor activity in ovarian, pancreatic and mesothelioma models. ....... [Mol Cancer Ther. 2014] - PubMed - NCBI -
Other ways to read this feed:Feed readerFacebook